Eysz is focused on enhancing the diagnosis and monitoring of brain disorders, particularly in pediatric populations. The company addresses the challenges faced in identifying conditions like ADHD and Childhood Absence Epilepsy (CAE), where symptoms can overlap and complicate diagnosis. Their flagship product, the Eysz Hyperventilation Recorder, is an FDA Class 1 registered software that allows healthcare professionals to digitally document hyperventilation procedures. This tool not only streamlines the diagnostic process but also adheres to established neurodiagnostic guidelines, ultimately improving access to child neurology services and reducing referral wait times significantly.

In addition to their software solutions, Eysz is engaged in rigorous research to validate their technologies. They have completed several studies, including a proof-of-concept study demonstrating the efficacy of eye-tracking in detecting absence seizures. Supported by grants from the NIH and NSF, Eysz is conducting further studies to analyze eye movement data during hyperventilation and assess comorbidities in epilepsy. These research initiatives aim to refine diagnostic algorithms and enhance the accuracy of seizure detection, thereby contributing to better patient outcomes and more efficient healthcare practices.

United States

We exist because we want to positively impact the lives of the 1 Billion people living with neurological disorders.

We are a team of doctors and doers that are on a mission to develop and deploy our AI-based clinical decision support tool that analyzes passive eye-movements to give clinicians the data they need to effectively manage the neurological health of their patients...starting with Epilepsy.

Eysz

Company Details